Skip to main content
Clinical Trials/NCT02112240
NCT02112240
Withdrawn
Not Applicable

Novel Sentinel Lymph Node Mapping Technique in Early Stage Rectal Cancer

University of Virginia1 site in 1 countryStarted: May 2013Last updated:

Overview

Phase
Not Applicable
Status
Withdrawn
Locations
1
Primary Endpoint
Evaluating the sensitivity of identifying the sentinel lymph node using a unique mobile gamma camera intraoperatively.

Overview

Brief Summary

The purpose of this study is to see if investigators can develop a technique to identify sentinel lymph nodes in the rectum for rectal cancer patients with the use of a radiotracer (Tc-sulfur colloid), a dye (Spot), and imaging, both pre- and intraoperatively. Eligible patients are those with stage I-III rectal cancer undergoing standard low anterior resection or abdominoperineal resection.

Investigators hypothesize that use of a unique intraoperative lymphatic mapping technique using a mobile gamma camera will identify the sentinel lymph node in patients with rectal cancer with greater than 80% sensitivity.

Subjects will receive injections of the tracer and dye prior to surgery, have preoperative SPECT/CT imaging to be used as a guide to the rectal lymphatic system and then proceed to their scheduled surgery. During surgery, images of the rectum will be taken with a unique mobile gamma camera prior to removal and upon resection.

If surgeons are able to identify the sentinel lymph nodes surrounding the rectal tumor, the hope is to combine this technique with a less invasive surgery called transanal endoscopic microsurgery (TEM) for early stage rectal cancer patients.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult patients with stage I,II, or III rectal cancer undergoing standard trans- abdominal low anterior resection or abdominoperineal resection surgery at the University of Virginia
  • Willing and able to give written informed consent

Exclusion Criteria

  • Patients less than 18 years of age
  • Women who are pregnant and/or breastfeeding
  • Prisoners
  • Unable to give written informed consent
  • Participants with medical contradictions or have potential problems complying with the requirements of the protocol, in the opinion of the investigator

Arms & Interventions

Surgery with pre- and intra-op imaging

Experimental

Subjects will have a preoperative flexible sigmoidoscopy where they will receive an endoscopic injection of 99mTc-sulfur colloid (up to 0.5 mCi) and 3 to 5 cc of circumferential endoscopic injections of Spot. A SPECT/CT will be performed prior to surgery to identify lymph nodes in the rectum. Subjects will proceed to their standard surgery. Intraoperative mobile gamma camera imaging of the rectum will occur before and after resection in attempt to identify sentinel lymph nodes.

Intervention: Intraoperative Mobile Gamma Camera imaging (Other)

Surgery with pre- and intra-op imaging

Experimental

Subjects will have a preoperative flexible sigmoidoscopy where they will receive an endoscopic injection of 99mTc-sulfur colloid (up to 0.5 mCi) and 3 to 5 cc of circumferential endoscopic injections of Spot. A SPECT/CT will be performed prior to surgery to identify lymph nodes in the rectum. Subjects will proceed to their standard surgery. Intraoperative mobile gamma camera imaging of the rectum will occur before and after resection in attempt to identify sentinel lymph nodes.

Intervention: Endoscopic injection of 99mTc-sulfur colloid (Drug)

Surgery with pre- and intra-op imaging

Experimental

Subjects will have a preoperative flexible sigmoidoscopy where they will receive an endoscopic injection of 99mTc-sulfur colloid (up to 0.5 mCi) and 3 to 5 cc of circumferential endoscopic injections of Spot. A SPECT/CT will be performed prior to surgery to identify lymph nodes in the rectum. Subjects will proceed to their standard surgery. Intraoperative mobile gamma camera imaging of the rectum will occur before and after resection in attempt to identify sentinel lymph nodes.

Intervention: Endoscopic injections of Spot (Other)

Surgery with pre- and intra-op imaging

Experimental

Subjects will have a preoperative flexible sigmoidoscopy where they will receive an endoscopic injection of 99mTc-sulfur colloid (up to 0.5 mCi) and 3 to 5 cc of circumferential endoscopic injections of Spot. A SPECT/CT will be performed prior to surgery to identify lymph nodes in the rectum. Subjects will proceed to their standard surgery. Intraoperative mobile gamma camera imaging of the rectum will occur before and after resection in attempt to identify sentinel lymph nodes.

Intervention: Preoperative flexible sigmoidoscopy (Procedure)

Surgery with pre- and intra-op imaging

Experimental

Subjects will have a preoperative flexible sigmoidoscopy where they will receive an endoscopic injection of 99mTc-sulfur colloid (up to 0.5 mCi) and 3 to 5 cc of circumferential endoscopic injections of Spot. A SPECT/CT will be performed prior to surgery to identify lymph nodes in the rectum. Subjects will proceed to their standard surgery. Intraoperative mobile gamma camera imaging of the rectum will occur before and after resection in attempt to identify sentinel lymph nodes.

Intervention: SPECT/CT (Radiation)

Outcomes

Primary Outcomes

Evaluating the sensitivity of identifying the sentinel lymph node using a unique mobile gamma camera intraoperatively.

Time Frame: At the time of surgery and the time of pathological review, an expected average of 7 days.

The primary endpoint is the sensitivity of sentinel lymph node (SLN) detection by the technique which will be estimated by the number of SLNs detected by the technique divided by the number noted at surgery or on final pathology review. 90% confidences interval around the estimate will help guide interpretation of the results.

Secondary Outcomes

  • Feasibility(From the time of tracer and dye injections to 30 day postoperative visit)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Traci Hedrick, MD

Assistant Professor of Surgery

University of Virginia

Study Sites (1)

Loading locations...

Similar Trials